Myriad Genetics, Inc.
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| MYGN | PSNL | NEO | BLLN | IMDX | BDSX | |
|---|---|---|---|---|---|---|
| Market cap | 575.81M | 1.69B | 2.22B | 5.37B | 86.72M | 226.74M |
| P/E (TTM) | — | — | — | 180.8 | — | — |
| Forward P/E | -10.2 | -16.3 | 54.5 | 76.7 | -3.3 | -97.7 |
| Price/book | 1.9 | 6.2 | 2.8 | 9.9 | -4.1 | 24.8 |
| Dividend yield | — | — | — | — | — | — |
| 1-year change | −4.90% | +119.76% | +64.90% | +4.54% | −59.23% | +175.87% |
| Today | −0.33% | +0.25% | +1.90% | +3.11% | −3.28% | +2.09% |
The closest companies by business and industry (Diagnostics & Research). Prices may be delayed up to 15 min.
Latest news
All MYGN news ›Myriad Genetics (NASDAQ:MYGN) reports upbeat Q3 2026, stock jumps 10.7%
Genetic testing company Myriad Genetics (NASDAQ:MYGN) reported Q3 2026 results beating Wall Street’s revenue expectations, but revenue fell by 1.5% year on year to $202.7 million. The company’s full-year revenue guidance of $785 million at…
Myriad Genetics (NASDAQ:MYGN) Stock Falls 7% – Should You Sell?
Posted by Danessa Lincoln on Nov 4th, 2026 Shares of Myriad Genetics, Inc. (NASDAQ:MYGN – Get Free Report) fell 7% on Monday. The company traded as low as $6.02 and last traded at $5.9040. 158,750 shares traded hands during trading, a…
Direct-to-Consumer (DTC) Genetic Testing Market 2025-2030 | Top Manufacturers; Family Tree DNA; Ancestry; EasyDNA; Myriad Genetics Inc.; Full Genomes Corporation, Inc.; Living DNA
Direct-to-Consumer (DTC) Genetic Testing Market 2025-2030 | openPR.com Direct-to-Consumer (DTC) Genetic Testing Market 2025-2030 | Top Manufacturers; Family Tree DNA; Ancestry; EasyDNA; Myriad Genetics Inc.; Full Genomes Corporation, Inc.;…
Myriad Genetics Sued for Misclassification of Genetic Variant
Myriad Sued for Allegedly Misclassifying Patient’s Gene Variant GenomeWeb Myriad Sued for Allegedly Misclassifying Patientâs Gene Variant
Myriad Genetics and Labcorp Announce Definitive Agreement for Myriad to Sell Prenatal Health Testing Business to Labcorp
When complete, the transaction is expected to provide more patients and physicians with expanded access to Labcorp’s comprehensive, high-quality laboratory services, convenient patient service center network, robust data analytics and…
Myriad Genetics Releases New MONSTAR-SCREEN-3 Data Demonstrating the Potential of Ultra-Sensitive MRD Detection in Colorectal and Pancreatic Cancers
SALT LAKE CITY, Oct. 22, 2026 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision ... Myriad Genetics Releases New MONSTAR-SCREEN-3 Data Demonstrating the Potential of…
More from 1 other outlet
Myriad Genetics to Release Third Quarter 2026 Financial Results on November 4, 2026
Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, will hold its third quarter 2026 earnings conference call at 4:30 pm ET on Wednesday, November 4 ... Myriad Genetics to Release Third…
TD says Myriad Genetics prenatal divestiture proceeds ahead of expectations
After Myriad Genetics (MYGN) announced a deal to sell its Prenatal Health testing business to Labcorp (LH) for $210M in cash plus closing invent... TD says Myriad Genetics prenatal divestiture proceeds ahead of expectations After Myriad…
Myriad Genetics: Prenatal Sale Provides A Lifeline In A Tough Spot
Myriad Genetics sells its prenatal testing business to boost liquidity, but losses persist. Click here to read this latest analysis of MYGN stock. - Myriad Genetics sold its prenatal health testing business to Labcorp for $210 million,…
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Themes
Most coverage from
- markets.businessinsider.com7
- themarketsdaily.com4
- stockstory.org3
- biospace.com1
- businessnewsthisweek.com1
Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 29 articles, not a forecast.